TL;DR
Get kitchen staples and gadgets delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Food Safety News publisher has called on the FDA to make two changes through citizen petitions: disclose company names and more location information in foodborne-outbreak summaries. The supplied report says the FDA has cited trade-secret protections for withholding company identities; the petitions’ full text and the agency’s response are not included in the source material.
Food Safety News publisher asked the Food and Drug Administration to disclose more identifying details in foodborne-outbreak reports, arguing that company names and locations should be public when investigations are closed. The request, described in a publisher’s platform article as two citizen petitions, tests the agency’s stated commitment to transparency against its practice of withholding details in some outbreak summaries.
The publisher says the petitions ask for actions the federal government has already taken or said it supports. He also writes that, as of October 26, 2026, the Department of Justice had not told the FDA it lacked authority to make the requested disclosures. The supplied report does not reproduce the petitions or specify their complete requested changes, so their precise scope cannot be independently assessed from this material.
The argument focuses on FDA’s Executive Incident Summary abstracts, introduced in September 2025 for closed outbreak investigations. The publisher credits the summaries as progress but says they omit information the public needs, particularly who was involved and where. He cites reporting that FDA withheld company names in a mango outbreak summary and that key details, including patients’ states, were redacted in a summary of a fatal Listeria outbreak.
The publisher also describes a February petition by Stop Foodborne Illness asking the FDA not to treat company names as confidential. According to his account, FDA replied that the names were protected by the Trade Secrets Act. He calls that an honest description of the agency’s legal concern, while arguing that the question has since been answered. The source excerpt does not explain the legal basis for that conclusion.
How Missing Details Affect Consumers
Names and locations can help people connect an official outbreak notice to a product, supplier or place they recognize. When those details are absent, consumers may find it harder to determine whether a warning concerns food they bought or an area where they live. The publisher’s central claim is that an investigation summary without identifying information can limit the practical value of public disclosure.
The examples in the article also point to a question of who communicates risk. The publisher says that in an October outbreak involving chicken wraps, the brand became public through a lawsuit and newspaper reporting rather than an FDA or USDA Food Safety and Inspection Service announcement. He says FSIS later confirmed the source to a reporter. The source excerpt does not provide the brand, the lawsuit, or the agency’s full account, so that description remains attributable to the publisher.
For the FDA, the dispute involves balancing public-health communication with legal limits on releasing business information. More disclosure could make outbreak reports easier to act on, while a change in policy would need to address the agency’s stated confidentiality concerns. Whether the petitions offer a legal route or proposed safeguards is not clear from the supplied material.
Products Worth Considering
Instant Pot Pro 8 Qt 10-in-1 Electric Pressure Cooker, Black
Instant Pot Vortex Plus 6-Quart 6-in-1 Air Fryer
Instant Pot InstantChill Plus Ice Cream Maker, 2-Pint
As an affiliate, we earn on qualifying purchases.
FDA’s Transparency Commitments
The publisher places the request within a series of public statements by officials in the Department of Health and Human Services and the FDA. He recounts that Robert F. Kennedy Jr. promised “radical transparency” during his January 2025 confirmation hearings and said Americans should be told when officials do not know something. In February 2025, Kennedy described transparency as necessary for informed consent.
In March 2025, HHS directed the FDA to explore ending the self-affirmed generally recognized as safe pathway for food ingredients. The department’s announcement said the agencies were committed to transparency so Americans would know what was in their food. In July, the FDA used similar language in a letter to food industry leaders about recall communications, specifically connecting transparency to food safety and nutrition actions.
The FDA’s food program later introduced the outbreak abstracts. The publisher notes that the program was then led by Kyle Diamantas, who is now acting FDA commissioner, according to the report. Former commissioner Marty Makary resigned in May 2026; President Donald Trump nominated Heidi Overton for the role in August, the article says. These leadership changes matter to the publisher’s case because he argues the agency’s written transparency commitments remain in place across administrations and officials.
“At the FDA, we believe that radical transparency in food safety and nutrition actions is key to reducing foodborne illness and chronic disease.”
— The FDA, in a July 2025 letter to food industry leaders, as quoted in the report
Petition Details and Legal Basis
The supplied article excerpt ends during its account of the October chicken-wrap outbreak and does not include the full argument or the text of either petition. It is therefore unclear exactly what disclosures each petition requests, what legal reasoning supports the publisher’s view, and which records or outbreak summaries the proposals would cover.
The FDA’s reported reliance on the Trade Secrets Act is presented through the publisher’s account of its response to Stop Foodborne Illness. The material does not include the agency’s response to the publisher’s two petitions, any DOJ opinion, or an FDA explanation of whether it considers the legal question resolved. The source also does not establish whether identifying a company in a summary would affect an active investigation or be limited to cases the FDA has closed.
FDA Response and Petition Review
The next concrete development would be the FDA’s response to the two citizen petitions, including whether the agency accepts the requests, denies them, or seeks additional time to review them. The supplied material does not give filing dates, petition docket numbers, or an expected decision schedule.
Readers can also expect the debate to turn on the agency’s explanation of what information it can release and when. Until the petitions and any FDA response are available, the requested policy change and its legal effect remain unsettled. The underlying question is whether closed-outbreak summaries will continue to omit company and location details or provide more information to the public.
Key Questions
What is the publisher asking the FDA to do?
The publisher says he submitted two citizen petitions seeking more identifying information in FDA foodborne-outbreak summaries, particularly company names and locations. The supplied source excerpt does not include the complete petitions, so the exact wording and scope are unclear.
Why does the FDA withhold company names?
According to the publisher, the FDA told Stop Foodborne Illness that company names were protected by the Trade Secrets Act. The source material does not include the full agency response or explain how the law applies to each type of outbreak record.
What are FDA Executive Incident Summary abstracts?
They are summaries the FDA food program began publishing in September 2025 about closed outbreak investigations. The publisher says the abstracts are a step forward but argues that some omit company identities and other details, including locations.
Has the FDA agreed to the new requests?
The supplied report does not say that the FDA has accepted the petitions or provide an agency response to them. The outcome and timing of any review are not established in the source material.
Source: foodsafetynews.com
